Table 1.
EudraVigilance | VAERS | ||||||||
---|---|---|---|---|---|---|---|---|---|
Exposed | Cases | R | RR 99% CI | Exposed | Cases | R | RR 99% CI | ||
Death cases | |||||||||
Agea, b | 18–64 Years | 183,061,142 | 3,759 | 2.053 | Ref. | 15,2704,862 | 1,781 | 1.166 | Ref. |
More than 65 Years | 63,473,405 | 11,209 | 17.659 | 8.60 [8.19–9.03] | 52,777,199 | 5,297 | 10.037 | 8.61 [8.02–9.23] | |
Sex | Female | 123267273.5 | 7,202 | 5.843 | Ref. | 102,741,030 | 3,029 | 2.948 | Ref. |
Male | 123267273.5 | 8,330 | 6.758 | 1.16 [1.11–1.21] | 10,2741,030 | 3,970 | 3.864 | 1.31 [1.23–1.39] | |
COVID vaccine | Astra | 34,643,783 | 3,574 | 10.316 | 2.09 [1.88–2.32] | ||||
Janssen | 14,723,578 | 727 | 4.938 | Ref. | 17,509,539 | 636 | 3.632 | Ref. | |
Moderna | 24957523 | 3680 | 14.745 | 2.99 [2.69–3.32] | 80561024 | 3238 | 4.019 | 1.11 [0.99–1.24] | |
Pfizer | 172,209,328 | 7,929 | 4.604 | 0.93 [0.84–1.03] | 107,411,499 | 3204 | 2.983 | 0.82 [0.73–0.92] | |
All COVID vaccines | 246,534,547 | 15,910 | 6.453 | 42.53 [33.49–54.01] | 205,482,061 | 7,078 | 3.445 | 345.42 [224.61–531.20] | |
Influenza vaccines | 7.71e+07 | 117 | 0.152 | Ref. | 3.61e+08 | 36 | 0.01 | Ref. | |
Hospitalisations | |||||||||
Age | 18–64 Years | 183,061,142 | 54,786 | 29.928 | Ref. | 15,2704,862 | 16,990 | 11.126 | Ref. |
More than 65 Years | 63,473,405 | 33,872 | 53.364 | 1.78 [1.75–1.82] | 52,777,199 | 16,799 | 31.83 | 2.86 [2.78–2.94] | |
Sex | Female | 123267273.5 | 51,885 | 42.091 | Ref. | 102,741,030 | 17,862 | 17.385 | Ref. |
Male | 123267273.5 | 39,879 | 32.352 | 0.77 [0.76–0.78] | 10,2741,030 | 15,812 | 15.39 | 0.89 [0.86–0.91] | |
COVID vaccine | Astra | 34,643,783 | 25,453 | 73.471 | 2.56 [2.45–2.67] | ||||
Janssen | 14,723,578 | 4,231 | 28.736 | Ref. | 17,509,539 | 3,670 | 20.96 | Ref. | |
Moderna | 24,957,523 | 19,864 | 79.591 | 2.77 [2.65–2.89] | 80561024 | 13628 | 16.916 | 0.81 [0.77–0.85] | |
Pfizer | 172209328 | 43420 | 25.214 | 0.88 [0.84–0.91] | 107,411,499 | 16,491 | 15.353 | 0.73 [0.70–0.77] | |
All COVID vaccines | 246534547 | 92968 | 37.71 | 45.71 [41.26–50.65] | 205,482,061 | 33,789 | 16.444 | 189.65 [163.85–219.53] | |
Influenza vaccines | 7.71e+07 | 636 | 0.825 | Ref. | 3.61e+08 | 313 | 0.087 | Ref. | |
Life-threatening reactions | |||||||||
Age | 18–64 Years | 18,3061,142 | 13,997 | 7.646 | Ref. | 152,704,862 | 57,07 | 3.737 | Ref. |
More than 65 Years | 63,473,405 | 7,248 | 11.419 | 1.49 [1.44–1.55] | 52,777,199 | 3,139 | 5.948 | 1.59 [1.50–1.69] | |
Sex | Female | 123267273.5 | 12,122 | 9.834 | Ref. | 102741030 | 4858 | 4.728 | Ref. |
Male | 123267273.5 | 9785 | 7.938 | 0.81 [0.78–0.84] | 102,741,030 | 3,958 | 3.852 | 0.81 [0.77–0.86] | |
COVID vaccine | Astra | 34,643,783 | 7,534 | 21.747 | 2.75 [2.54–2.99] | ||||
Janssen | 14723578 | 1163 | 7.899 | Ref. | 17509539 | 1108 | 6.328 | Ref. | |
Moderna | 249,57,523 | 4,336 | 17.374 | 2.20 [2.02–2.39] | 80,561,024 | 3535 | 4.388 | 0.69 [0.63–0.76] | |
Pfizer | 172,209,328 | 9,221 | 5.355 | 0.68 [0.63–0.73] | 107,411,499 | 4,203 | 3.913 | 0.62 [0.57–0.67] | |
All COVID vaccines | 246,534,547 | 22,254 | 9.027 | 56.13 [44.51–70.78] | 205,482,061 | 8,846 | 4.305 | 196.72 [147.04–263.19] | |
Influenza vaccines | 7.71e+07 | 124 | 0.161 | Ref. | 3.61e+08 | 79 | 0.022 | Ref. |
Ref: Reference category for the estimation of the relative risks.
The number of exposed individuals aged 18 to 64 years in the European Union corresponds to the interval 18–69 years since the official EU statistics on vaccination coverage contains only 10-year age intervals.
Germany, Liechtenstein and Netherlands supply total numbers only. Based on national health authorities estimates, the number of exposed individuals in the 18–69 age interval is about 60%.